Drugs / SKB500
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06736327 | Dec 2024 → Jul 2027 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07700667 | Jul 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07296809 | Jan 2026 → Dec 2028 expected | small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07700667 ↗ |
| Route | Intravenous | “The administration route of SKB500 is intravenous infusion” NCT06736327 ↗ |